• Hematopoietic stem cell transplantation and associated risk factors precipitate endothelial injury, leading to HSCT-TMA and other endothelial injury syndromes such as hepatic veno-occlusive disease/sinusoidal obstruction syndrome, idiopathic pneumonia syndrome, diffuse alveolar hemorrhage, capillary leak syndrome, and graft-versus-host disease. (biomedcentral.com)
  • The representative situations include evaluation of vascular problems in cancer sufferers such as for example catheter-related deep vein thrombosis (DVT) and equivocal pulmonary embolism (PE) evaluation of oncologic sufferers with acutely raised liver function test outcomes due to several causes including drug-induced hepatobiliary disease portal vein thrombosis and hepatic veno-occlusive disease and evaluation of unusual uterine bleeding mostly in breast cancer tumor sufferers. (buyresearchchemicalss.net)
  • In general, the presence of elevated fibrin degradation products, thrombocytopenia, and sometimes opening and severe post-transplant sinusoidal obstruction syndrome formerly termed hepatic veno-occlusive disease after six months, thrombocytosis and more than atypical lymphocytes are not reliable for showing the transmission of cmv. (albionfoundation.org)
  • Idiopathic pulmonary arterial hypertension (IPAH) is a rare disease characterized by elevated pulmonary artery pressure with no apparent cause. (medscape.com)
  • see 178600), a severe condition characterized by elevated pulmonary artery pressure leading to right heart failure and death. (nih.gov)
  • Diagnosis is made by finding elevated pulmonary artery pressure (estimated by echocardiography and confirmed by right heart catheterization). (msdmanuals.com)
  • Risk factors include a family history, prior pulmonary embolism (blood clots in the lungs), HIV/AIDS, sickle cell disease, cocaine use, chronic obstructive pulmonary disease, sleep apnea, living at high altitudes, and problems with the mitral valve. (wikipedia.org)
  • Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI ® to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (janssencarepath.com)
  • Pulmonary Embolism (PE) Pulmonary embolism (PE) is the occlusion of pulmonary arteries by thrombi that originate elsewhere, typically in the large veins of the legs or pelvis. (msdmanuals.com)
  • Risk factors for pulmonary embolism are. (msdmanuals.com)
  • According to the definition at the 6th World Symposium of Pulmonary Hypertension in 2018, a patient is deemed to have pulmonary hypertension if the pulmonary mean arterial pressure is greater than 20mmHg at rest, revised down from a purely arbitrary 25mmHg, and pulmonary vascular resistance (PVR) greater than 3 Wood units. (wikipedia.org)
  • Pulmonary hypertension (PH) is an elevation of pulmonary arterial pressure, which can be due to heart, lung, or systemic disorders. (jrenhep.com)
  • Pulmonary veno-occlusive disease (PVOD) is one of the less commonly encountered causes of pulmonary hypertension . (medscape.com)
  • Some reports suggest that PVOD accounts for 5-20% of cases classified as idiopathic pulmonary arterial hypertension (PAH). (medscape.com)
  • In the past, PVOD has been described by various terms, such as pulmonary venous sclerosis, obstructive disease of the pulmonary veins, or the venous form of primary pulmonary hypertension. (medscape.com)
  • Regardless of the mechanism of injury, the end result in pulmonary veno-occlusive disease (PVOD) is constriction and/or occlusion of the pulmonary veins and venules. (medscape.com)
  • The exact etiology of pulmonary veno-occlusive disease (PVOD) remains largely unknown. (medscape.com)
  • Some cases of pulmonary hypertension in the setting of mixed connective disease and scleroderma , including the CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) variant, have been known to have a histopathology consistent with that of PVOD. (medscape.com)
  • Pulmonary veno-occlusive disease (PVOD) is defined by specific pathologic changes of the pulmonary veins. (nih.gov)
  • A definite diagnosis of PVOD thus requires a lung biopsy or pathologic examination of pulmonary explants or postmortem lung samples. (nih.gov)
  • Patients with PVOD may be refractory to pulmonary arterial hypertension (PAH)-specific therapy and may even deteriorate with it. (nih.gov)
  • High-resolution computed tomography of the chest can suggest PVOD in the setting of pulmonary hypertension when it shows nodular ground-glass opacities, septal lines, lymph node enlargement, and pleural effusion. (nih.gov)
  • Similarly, occult alveolar hemorrhage found on bronchoalveolar lavage in patients with pulmonary hypertension is associated with PVOD. (nih.gov)
  • We retrospectively reviewed 48 cases of severe pulmonary hypertension: 24 patients with histologic evidence of PVOD and 24 randomly selected patients with idiopathic, familial, or anorexigen-associated PAH and no evidence of PVOD after meticulous lung pathologic evaluation. (nih.gov)
  • Among the 16 PVOD patients who received PAH-specific therapy, 7 (43.8%) developed pulmonary edema (mostly with continuous intravenous epoprostenol, but also with oral bosentan and oral calcium channel blockers) at a median of 9 days after treatment initiation. (nih.gov)
  • The pathologic hallmark of PVOD is the extensive and diffuse occlusion of pulmonary veins by fibrous tissue, with intimal thickening present in venules and small veins in lobular septa and, rarely, larger veins. (nih.gov)
  • The biopsy from patient 2 exhibited focal features of sinusoidal obstructive syndrome (veno-occlusive disease) with pericentral confluent necrosis. (substack.com)
  • Pulmonary hypertension (PH) is a fatal disorder characterized by an increase in pulmonary vascular resistance, which leads to right ventricular failure. (jrheum.org)
  • Pulmonary arterial hypertension is a rare and incurable chronic disease characterised by a progressive increase in pulmonary vascular resistance and right heart failure. (ersjournals.com)
  • However, lung biopsy is hazardous in patients with severe pulmonary hypertension, and there is a need for noninvasive diagnostic tools in this patient population. (nih.gov)
  • The "European Respiratory Society/American Thoracic Society Task Force on Undifferentiated Forms of Connective Tissue Disease-associated Interstitial Lung Disease" was formed to create consensus regarding the nomenclature and classification criteria for patients with IIP and features of autoimmunity. (ersjournals.com)
  • The primary objective of this multidisciplinary task force was to develop consensus surrounding the nomenclature and classification of patients with suggestive forms of connective tissue disease-associated interstitial lung disease (CTD-ILD). (ersjournals.com)
  • These guidelines are endorsed by the International Society for Heart and Lung Transplantation, and provide the current framework for understanding and treatment of pulmonary hypertension. (wikipedia.org)
  • Precapillary PH was found in 64 patients (5%), of whom 42 had pulmonary arterial hypertension (PAH) and 22 had PH secondary to interstitial lung disease (ILD). (jrheum.org)
  • Obstructive proliferative vasculopathy of the small and medium-size pulmonary arterial circulation and chronic hypoxemia due to advanced lung disease are major causes of precapillary PH in SSc 7 , 8 . (jrheum.org)
  • Unexplained ground glass opacities, interstitial lung disease, and/or pulmonary granulomas. (primaryimmune.org)
  • Nuclear lung ventilation/perfusion scanning: This is performed to exclude chronic thromboembolic pulmonary hypertension (Group IV PH). (medscape.com)
  • Lung transplantation in children with idiopathic pulmonary arterial hypertension. (medscape.com)
  • Pulmonary edema can be life-threatening, but effective therapy is available to rescue patients from the deleterious consequences of disturbed lung fluid balance, which usually can be identified and, in many instances, corrected. (thoracickey.com)
  • Lung structure relevant to the forces governing fluid and protein movement in healthy lungs and lungs with pulmonary edema has been the subject of classic and more recent reviews. (thoracickey.com)
  • While these results are not what we hoped for, we are proud of the foundational role that KEYTRUDA has established in the treatment of certain types of lung cancer, and we are committed to continuing to research how we can further improve responses to our medicines for patients with difficult-to-treat forms of the disease. (streetinsider.com)
  • Pulmonary surfactant metabolism dysfunction-5 (SMDP5) is an autosomal recessive lung disorder manifest clinically and pathologically as pulmonary alveolar proteinosis (PAP). (nih.gov)
  • PAP is a rare lung disease characterized by the ineffective clearance of surfactant by alveolar macrophages. (nih.gov)
  • Other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus, can lead to the development of pulmonary hypertension. (phsa.co.za)
  • Most children have prevention & treatment of obstructive lung disease, so increased doses ie, more than days may be depressed or overwhelmed. (albionfoundation.org)
  • Methods IDA in end-stage renal disease patients on HD was observed in 42 (33.6%) of 125 patients. (go.jp)
  • Normal individuals do not correlate strictly with the first months after birth, or it may be catastrophic as these children are more likely to have various renal cystic diseases, bleeding disorders, sickle cell disease. (elastizell.com)
  • Pulmonary renal syndromes, connective tissue disorders and drugs make up the majority of the cases of DAH. (medscape.com)
  • Acute vasodilator testing with nitric oxide and clinical, functional, or hemodynamic characteristics were not predictive of the subsequent occurrence of pulmonary edema on treatment. (nih.gov)
  • Pulmonary edema-defined as excessive extravascular water in the lungs-is a common and serious clinical problem. (thoracickey.com)
  • Because rational and effective therapy depends on understanding basic principles of normal and abnormal liquid, solute, and protein transport in the lungs, this chapter begins with a brief overview of the major factors that govern fluid and protein filtration in healthy lungs before focusing on the pathophysiology of pulmonary edema. (thoracickey.com)
  • Pulmonary edema results when fluid is filtered into the lungs faster than it can be removed from them. (thoracickey.com)
  • Consider the use of prophylactic steroids to mitigate Systemic Inflammatory Response Syndrome (SIRS) or capillary leak syndrome (e.g., hypotension, tachycardia, tachypnea, and pulmonary edema). (guidelinecentral.com)
  • Discontinue Clolar administration if a patient shows early signs or symptoms of SIRS or capillary leak syndrome (e.g., hypotension, tachycardia, tachypnea, and pulmonary edema) occur and provide appropriate supportive measures. (guidelinecentral.com)
  • VELETRI ® should not be used chronically in patients who during dose initiation develop pulmonary edema, which may be associated with pulmonary veno-occlusive disease. (janssencarepath.com)
  • 56782] Prophylactic medications should only be considered for individuals with a history of high altitude pulmonary edema. (cialis-canadian-pharma.com)
  • The plexiform arterial lesions seen in patients with primary pulmonary hypertension, or idiopathic pulmonary arterial hypertension (PAH), are absent, although some arterial medial thickening may occur. (medscape.com)
  • IPAH is also termed WHO Group I pulmonary hypertension (PH), precapillary pulmonary hypertension, and, previously, primary pulmonary hypertension. (medscape.com)
  • Go to Primary Pulmonary Hypertension and Persistent Newborn Pulmonary Hypertension for more complete information on these topics. (medscape.com)
  • Barst R, Long W, Gersony W. Long-term vasodilator treatment improves survival in children with primary pulmonary hypertension. (medscape.com)
  • Pulmonary venous hypertension typically presents with shortness of breath while lying flat or sleeping (orthopnea or paroxysmal nocturnal dyspnea), while pulmonary arterial hypertension (PAH) typically does not. (wikipedia.org)
  • Consecutive patients with SSc recruited at 11 French and Italian centers underwent detailed evaluations, including Doppler echocardiography, chest computed tomography, pulmonary function tests, and right-heart catheterization (RHC), to detect the presence and causes of PH. (jrheum.org)
  • 0.05), but no difference in pulmonary capillary wedge pressure. (nih.gov)
  • Pulmonary artery pressure (PAP) is defined as a sustained elevation of PAP ≥ 25 mmHg at rest or ≥30 mmHg with exercise, with a mean pulmonary-capillary wedge pressure and left ventricular end-diastolic pressure of ≥15 mmHg ( 1 ). (jrenhep.com)
  • Coughing up of blood may occur in some patients, particularly those with specific subtypes of pulmonary hypertension such as heritable pulmonary arterial hypertension, Eisenmenger syndrome and chronic thromboembolic pulmonary hypertension. (wikipedia.org)
  • The clinical syndrome is characterized by hemoptysis, falling hematocrit, hypoxemic respiratory failure and diffuse pulmonary infiltrates. (medscape.com)
  • BACKGROUND: Alveolar macrophages (AMs) and AM-produced matrix metalloprotease (MMP)-12 are known to play critical roles in the pathogenesis of chronic obstructive pulmonary disease (COPD). (bvsalud.org)
  • Diffuse alveolar hemorrhage (DAH) is a life-threatening disorder characterized clinically by the presence of hemoptysis, falling hematocrit, diffuse pulmonary infiltrates and hypoxemic respiratory failure. (medscape.com)
  • Diffuse alveolar hemorrhage (DAH) is a life-threatening condition which refers to hemorrhage originating in the pulmonary microvasculature, rather than from the bronchial circulation or parenchymal abnormalities. (medscape.com)
  • Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure in the arteries of the lungs. (wikipedia.org)
  • A 1973 World Health Organization meeting was the first attempt to classify pulmonary hypertension by its cause, and a distinction was made between primary PH (resulting from a disease of the pulmonary arteries) and secondary PH (resulting secondary to other, non-vascular causes). (wikipedia.org)
  • Pulmonary Hypertension, or PH, is a disease affecting the arteries of the lungs. (phsa.co.za)
  • At the same time, the blood vessels carrying blood to the lungs (the pulmonary arteries) expand to allow more blood through. (phsa.co.za)
  • The pulmonary arteries do this by stretching slightly. (phsa.co.za)
  • In a person with PH, the walls of the pulmonary arteries are thicker, so are less able to stretch. (phsa.co.za)
  • Although the term pulmonary veno-occlusive disease was first used in the 1960s, the first case was described by Dr J. Hora in 1934 in a 48-year-old patient who died within one year of diagnosis with symptoms of right-sided heart failure. (medscape.com)
  • Because many of the symptoms of idiopathic pulmonary artery hypertension (IPAH) are nonspecific and the disorder is relatively rare, the diagnosis may be somewhat difficult to make. (medscape.com)
  • 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. (medscape.com)
  • Wilkes J. AHA/ATS Release Guidelines on the Diagnosis and Treatment of Pediatric Pulmonary Hypertension. (medscape.com)
  • VELETRI ® should be used only by clinicians experienced in the diagnosis and treatment of pulmonary hypertension. (janssencarepath.com)
  • Disease registries, which include patients based on diagnosis, have served as an important source of data for characterising the various subtypes of PAH, assessing the burden and outcome of the disease, identifying risk factors, generating and validating hypothesis and measuring quality assurance and compliance to guidelines [ 2 ]. (ersjournals.com)
  • PAH has different causes, it can be idiopathic, familial or associated with a number of conditions such as connective tissue disease, congenital heart disease, portal hypertension, HIV infection and exposure to toxins and drugs [ 1 ]. (ersjournals.com)
  • Certain drugs, such as methamphetamines and the diet drug "fen phen," are known to cause pulmonary hypertension. (phsa.co.za)
  • Many conditions and drugs cause pulmonary hypertension. (msdmanuals.com)
  • Severe pulmonary hypertension leads to right ventricular overload and failure. (msdmanuals.com)
  • Inborn errors of pulmonary surfactant metabolism are genetically heterogeneous disorders resulting in severe respiratory insufficiency or failure in full-term neonates or infants. (nih.gov)
  • These disorders are associated with various pathologic entities, including pulmonary alveolar proteinosis (PAP), desquamative interstitial pneumonitis (DIP), or cellular nonspecific interstitial pneumonitis (NSIP) (Clark and Clark, 2005). (nih.gov)
  • Many patients with an idiopathic interstitial pneumonia (IIP) have clinical features that suggest an underlying autoimmune process but do not meet established criteria for a connective tissue disease (CTD). (ersjournals.com)
  • Patients with ACVRL1 mutations who do develop PAH 7 are particularly young, have often rapid disease progression and have a worse prognosis than patients with BMPR2 mutations 10 . (nature.com)
  • To measure the prevalence of different types of pulmonary hypertension (PH) and to identify patients with systemic sclerosis (SSc) at highest risk in a multicenter European sample, with a metaanalysis of relevant studies. (jrheum.org)
  • RHC identified 17 patients (1%) with postcapillary PH secondary to left-heart disease. (jrheum.org)
  • The metaanalysis of 3818 patients showed a prevalence of precapillary PH of 9% (95% CI 6%-12%) and identified advanced age, longer disease duration, and limited cutaneous disease subset as risk factors for this condition. (jrheum.org)
  • In approximately a third of patients with pulmonary arterial hypertension (PAH), Doppler echocardiography demonstrates right-to-left shunting across a patent foramen ovale. (medscape.com)
  • Excluding left-sided heart disease, including diastolic dysfunction, is especially important in these patients because of major treatment implications. (medscape.com)
  • TORONTO - No significant associations exist between the 6-minute walk distance (6MWD) or percent predicted 6MWD (PP-6MWD) and peak oxygen uptake (VO2peak) as measured by cardiopulmonary exercise testing (CPET) in patients with pulmonary arterial hypertension (PAH), according to a study presented at CHEST 2017, held October 28-November 1 in Toronto, Ontario, Canada. (pulmonologyadvisor.com)
  • Of the patients included in the final analysis, mean pulmonary artery pressure was 56±8 mm Hg. (pulmonologyadvisor.com)
  • To study the incidence of pulmonary hypertension (PH) in chronic kidney disease (CKD) stage V patients on maintenance hemodialysis (HD) at our center. (jrenhep.com)
  • Before prescribing ADCIRCA, carefully consider whether patients with underlying cardiovascular disease could be adversely affected by such actions. (adcirca.com)
  • Sildenafil is a vasoactive agent that is commonly prescribed to treat erectile dysfunction (impotence) in men, and to reduce symptoms in patients with pulmonary arterial hypertension (PAH). (empowerpharmacy.com)
  • Shortly after approval for ED, studies showed sildenafil was effective in treating patients with pulmonary arterial hypertension (PAH). (empowerpharmacy.com)
  • Although preliminary data from 12 patients with sickle cell anemia showed a decrease in PAH, a larger clinical trial (n = 134) investigating the use of sildenafil for pulmonary hypertension in adults with sickle cell anemia was stopped early due to an increased risk of severe adverse effects, especially sickle cell pain crises, compared to placebo (38% vs. 8%, respectively). (empowerpharmacy.com)
  • KEYTRUDA was also granted accelerated approval in September 2019, and received full approval in July 2021, in combination with LENVIMA ® (lenvatinib) for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. (businesswire.com)
  • Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy. (keytrudahcp.com)
  • We remain committed to continued research in melanoma, both to further understand the potential benefit of Yervoy in combination with Opdivo to treat high-risk melanoma patients in the earlier stages of disease, as well as to study additional novel combinations in various settings. (bms.com)
  • Patients enrolled in the trial had no prior systemic anti-cancer treatment for melanoma, except surgery for the melanoma lesion(s) and/or adjuvant radiation therapy after neurosurgical resection for central nervous system lesions. (bms.com)
  • Evidence of tricuspid insufficiency and pulmonic regurgitation is also sought and, if present, is consistent with the presence of pulmonary hypertension. (wikipedia.org)
  • The medication was initially formulated to treat hypertension (a symptom of ischaemic heart disease) and chest pains caused from the inadequacy of the blood circulation to the heart. (empowerpharmacy.com)
  • It refers to bleeding that originates in the pulmonary microvasculature instead of the parenchyma or bronchial circulation. (medscape.com)
  • The resultant shunting of portal venous flow to the systemic circulation helps reduce the portosystemic gradient and alleviate bleeding and ascites without changing the extrahepatic anatomy. (capsulehealth.one)
  • Pulmonary hypertension is increased pressure in the pulmonary circulation. (msdmanuals.com)
  • The task force proposes the term "interstitial pneumonia with autoimmune features" (IPAF) and offers classification criteria organised around the presence of a combination of features from three domains: a clinical domain consisting of specific extra-thoracic features, a serologic domain consisting of specific autoantibodies, and a morphologic domain consisting of specific chest imaging, histopathologic or pulmonary physiologic features. (ersjournals.com)
  • Chest radiography: A chest radiograph may help identify secondary causes of, or contributors to, pulmonary hypertension. (medscape.com)
  • Treatment is with pulmonary vasodilators and diuretics. (msdmanuals.com)
  • Recurrent pulmonary infections particularly with unusual organisms. (primaryimmune.org)
  • Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. (medscape.com)
  • DAH is characterized clinically by hemoptysis, falling hematocrit, hypoxemic respiratory failure and diffuse pulmonary infiltrates. (medscape.com)
  • INTRODUCTION: Chronic thromboembolic pulmonary hypertension (CTEPH) results from unresolved thrombotic obstruction of the pulmonary vasculature. (bvsalud.org)
  • Because epoprostenol is metabolized rapidly, even brief interruptions in the delivery of VELETRI ® may result in symptoms associated with rebound pulmonary hypertension including dyspnea, dizziness, and asthenia. (janssencarepath.com)
  • Dosage of VELETRI ® during chronic use should be adjusted at the first sign of recurrence or worsening of symptoms attributable to pulmonary hypertension or the occurrence of adverse events associated with epoprostenol. (janssencarepath.com)
  • Abrupt withdrawal (including interruptions in drug delivery) or sudden large reductions in dosage of VELETRI ® may result in symptoms associated with rebound pulmonary hypertension, including dyspnea, dizziness, and asthenia. (janssencarepath.com)
  • Other individuals have a multitude of the most severe symptoms of end-stage liver disease and a limited chance for survival. (medscape.com)
  • Specific medical therapies may be applied to many liver diseases in an effort to diminish symptoms and to prevent or forestall the development of cirrhosis. (medscape.com)
  • In advanced stages of pulmonary hypertension, minimal activity may produce some or all of these symptoms. (phsa.co.za)
  • Sometimes these symptoms mean you have another condition, but sometimes, these symptoms mean you have pulmonary hypertension. (phsa.co.za)
  • Pulmonary hypertension (PH) can be difficult to diagnose in a routine medical examination because the most common symptoms of PH, such as breathlessness, fatigue and dizziness, are also associated with many other conditions. (phsa.co.za)
  • Further, primary PH was divided into the "arterial plexiform", "veno-occlusive" and "thromboembolic" forms. (wikipedia.org)
  • We present a case of a school-age female with sJIA who died of acute cardiopulmonary instability secondary to pulmonary venous-occlusive disease demonstrated by necropsy. (reumatologiaclinica.org)
  • The interest in PH due to systemic sclerosis (SSc), the connective tissue disease most often associated with PH, has recently increased 2 . (jrheum.org)
  • In addition, left-heart disease and thromboembolic disease may cause, respectively, postcapillary/venous and precapillary PH 10 , 11 . (jrheum.org)
  • Treatment depends on the type of disease. (wikipedia.org)
  • For diseases that require treatment over a longer period or in the long-term prophylaxis of diseases, it is desirable to keep the dosing frequency of medicaments as low as possible. (justia.com)
  • ADCIRCA ® (tadalafil) is a phosphodiesterase 5 inhibitor (PDE-5i) indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. (adcirca.com)
  • STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. (medscape.com)
  • VELETRI ® is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. (janssencarepath.com)
  • For the treatment of pulmonary hypertension to improve exercise ability in persons with WHO Group I pulmonary hypertension. (cialis-canadian-pharma.com)
  • PAH is characterized by progressive, obliterative remodeling of pulmonary arterioles, pre-capillary vessel loss, right heart failure and death. (nature.com)
  • In the first group (pulmonary arterial hypertension [PAH]), the primary disorder affects the small pulmonary arterioles. (msdmanuals.com)
  • Other typical signs of pulmonary hypertension include an accentuated pulmonary component of the second heart sound, a right ventricular third heart sound, and parasternal heave indicating a hypertrophied right ventricle. (wikipedia.org)
  • Typically, the echocardiogram demonstrates evidence of increased pulmonary arterial (PA) pressure, accompanied by an enlarged right ventricle (see the image below). (medscape.com)